A Phase Ib Dose Escalation Trial of Carfilzomib plus Bendamustine and Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Investigator: Charalambos (Babis) Andreadis, MD
Sponsor: National Comprehensive Cancer Network, Inc.

Location(s): United States


This study will be conducted as a Phase Ib, open-label, non-randomized, single-institution study to evaluate the safety and tolerability of carfilzomib in combination with bendamustine and rituximab in patients with relapsed or refractory NHL and to determine the recommended phase II dose and preliminary efficacy of this combination. The study will have two phases: a dose-escalation phase to determine the maximal tolerated dose of carfilzomib in this combination where participants will be monitored for toxicity, tolerability and response and a dose-expansion phase that will determine the preliminary efficacy in patients with Mantle cell lymphoma or any other disease subtype in which there is a preliminary efficacy signal observed.